Venetoclax
B-Cell Chronic Lymphocytic Leukemia
Explore 67 assets in B-Cell Chronic Lymphocytic Leukemia →Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Zulfa Omer
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07014917CT.gov Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL | — | Recruiting | — | — | — |
NCT07082452CT.gov A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction | — | Not Yet Recruiting | — | — | — |
NCT05963074CT.gov A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia | — | Recruiting | — | — | — |
NCT05947851CT.gov A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). | — | Recruiting | — | — | — |
NCT04941716CT.gov Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial | — | Recruiting | — | — | — |
NCT05650723CT.gov Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab | — | Active Not Recruiting | — | — | — |
NCT04608318CT.gov Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) | — | Active Not Recruiting | — | — | — |
NCT04512105CT.gov Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT03639324CT.gov Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL | — | Withdrawn | — | — | — |
NCT04515238CT.gov Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL | — | Active Not Recruiting | — | — | — |
Show 13 more trialsShow fewer
NCT04169737CT.gov Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | — | Recruiting | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT03766763CT.gov Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A | — | Active Not Recruiting | — | — | — |
NCT03787264CT.gov Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL | — | Completed | — | — | — |
NCT03755947CT.gov Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia | — | Completed | — | — | — |
NCT03462719CT.gov A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | — | Active Not Recruiting | — | — | — |
NCT03343678CT.gov This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax | — | Withdrawn | — | — | — |
NCT03331198CT.gov Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | — | Recruiting | — | — | — |
NCT03045328CT.gov Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL | — | Completed | — | — | — |
NCT03226301CT.gov A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations | — | Active Not Recruiting | — | — | — |
NCT02639910CT.gov Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi | — | Completed | — | — | — |
NCT02756897CT.gov Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia | — | Active Not Recruiting | — | — | — |
NCT02401503CT.gov Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Cell Chronic Lymphocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Venetoclax (this asset) | Zulfa Omer | P3 | BB · 66 |
| Humax-Cd20 | Emory University | P4 | BBB |
| Acalabrutinib | Zulfa Omer | P4 | BBB |
| Fludarabine | Ohio State University Comprehensive Cancer Center | P4 | BBB |
| Rituximab | Zulfa Omer | P4 | BBB |
| Cyclophosphamide | Ohio State University Comprehensive Cancer Center | P4 | BBB |
| Cediranib | City of Hope Medical Center | P2 | BB |
| Obinutuzumab | Paolo Caimi, MD | P3 | BB |
| Bendamustine | Mayo Clinic | P3 | BB |
+42 more in the B-Cell Chronic Lymphocytic Leukemia cohort
Other indications for Venetoclax
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P4 | BB · 70 |
| Acute Myeloid Leukemia | — | P4 | BB · 69 |
| Chronic Myelomonocytic Leukemia | — | P2/3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Venetoclax in B-Cell Chronic Lymphocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/venetoclax-b-cell-chronic-lymphocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →